NZ729408A - A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine - Google Patents

A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine

Info

Publication number
NZ729408A
NZ729408A NZ729408A NZ72940815A NZ729408A NZ 729408 A NZ729408 A NZ 729408A NZ 729408 A NZ729408 A NZ 729408A NZ 72940815 A NZ72940815 A NZ 72940815A NZ 729408 A NZ729408 A NZ 729408A
Authority
NZ
New Zealand
Prior art keywords
cytokine
antigenic molecule
pci
utilizing
photosensitizing agent
Prior art date
Application number
NZ729408A
Other languages
English (en)
Inventor
Anders Høgset
Pål Johansen
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201415247A external-priority patent/GB201415247D0/en
Priority claimed from GB201420773A external-priority patent/GB201420773D0/en
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of NZ729408A publication Critical patent/NZ729408A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ729408A 2014-08-28 2015-08-28 A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine NZ729408A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201415247A GB201415247D0 (en) 2014-08-28 2014-08-28 Compound and method
GB201420773A GB201420773D0 (en) 2014-11-21 2014-11-21 Compound and method
PCT/EP2015/069794 WO2016030529A1 (en) 2014-08-28 2015-08-28 Compound and method

Publications (1)

Publication Number Publication Date
NZ729408A true NZ729408A (en) 2021-12-24

Family

ID=54065872

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ729408A NZ729408A (en) 2014-08-28 2015-08-28 A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine

Country Status (9)

Country Link
US (1) US10537639B2 (cg-RX-API-DMAC7.html)
EP (1) EP3185901B1 (cg-RX-API-DMAC7.html)
JP (2) JP2017526371A (cg-RX-API-DMAC7.html)
KR (1) KR102678732B1 (cg-RX-API-DMAC7.html)
CN (1) CN108136016A (cg-RX-API-DMAC7.html)
AU (1) AU2015308345B9 (cg-RX-API-DMAC7.html)
BR (1) BR112017003486A2 (cg-RX-API-DMAC7.html)
NZ (1) NZ729408A (cg-RX-API-DMAC7.html)
WO (1) WO2016030529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
US20220314021A1 (en) 2019-02-19 2022-10-06 Otsuka Electronics Co., Ltd. Method for determining condition parameters for photodynamic therapy and photodynamic therapy apparatus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
EP1346059B1 (en) 2000-11-29 2012-05-23 PCI Biotech AS Photochemical internalization for delivery of molecules into the cytosol
MXPA03005373A (es) 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
WO2005100547A1 (ja) * 2004-04-06 2005-10-27 Techno Network Shikoku Co., Ltd. 抗原パルスして得られた樹状細胞
WO2005097976A1 (ja) 2004-04-06 2005-10-20 Ehime University 抗原パルスして得られた樹状細胞
JP2011522837A (ja) 2008-06-06 2011-08-04 ベイラー リサーチ インスティテュート 呼吸器多核体ウイルスによる樹状細胞の寛容誘導
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
GB201208548D0 (en) * 2012-05-15 2012-06-27 Pci Biotech As Compound and method
US20160040128A1 (en) * 2013-03-15 2016-02-11 Pci Biotech As Method
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
JP6684215B2 (ja) * 2013-08-28 2020-04-22 ピーシーアイ バイオテック エイエス 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法
AU2014390262B2 (en) * 2014-04-11 2020-11-26 Pci Biotech As Method of treating melanoma

Also Published As

Publication number Publication date
CA2959207A1 (en) 2016-03-03
AU2015308345B2 (en) 2020-12-10
JP7079819B2 (ja) 2022-06-02
JP2017526371A (ja) 2017-09-14
US10537639B2 (en) 2020-01-21
KR102678732B1 (ko) 2024-06-25
EP3185901B1 (en) 2023-10-04
EP3185901C0 (en) 2023-10-04
BR112017003486A2 (en) 2018-01-16
CN108136016A (zh) 2018-06-08
JP2020182486A (ja) 2020-11-12
WO2016030529A1 (en) 2016-03-03
KR20170047336A (ko) 2017-05-04
AU2015308345B9 (en) 2020-12-24
AU2015308345A1 (en) 2017-03-16
EP3185901A1 (en) 2017-07-05
US20170252441A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
MX374472B (es) Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018002344A (es) Metodo para tratar el cancer.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
MX2015010783A (es) Composicion de vacuna.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
EP3998341A3 (en) Adenoviral vectors
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20220817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20230815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2025 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20240821

LAPS Patent lapsed